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ABSTRACT
Introduction: Basal cell carcinoma (BCC) is the
most common form of skin cancer; however,
few data are available relating to patients’
perspectives and experiences of this disease.
This study explored the spectrum of BCC
symptoms and their impact by disease stage to
determine how BCC affects the overall
health-related quality of life (HRQL) of patients.
Methods: This study comprised a
cross-sectional, qualitative approach involving
telephone interviews with patients with BCC
who had been divided into two groups: group 1
(G1), patients with stage 1, non-advanced BCC
(and of superficial or nodular histology); and
group 2 (G2), patients with locally advanced or
metastatic BCC. Patients were recruited from
three clinical sites in the USA based on a
separate qualitative interview study
(I4J-MC-HHBB [1.3]) over a 10-month period.
Techniques in qualitative methodology were
used by applying ‘open-ended’ questions and
probing techniques intended to elicit patients’
own description of their experiences with BCC.
Telephone interviews lasted between 60 and
90 mins.
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Results: Thirty-four interviews were conducted
(G1: N = 13; G2: N = 21). The majority of
patients were aged either 55–64 years (32%,
N = 11) or 76? years (32%, N = 11) and were
primarily male (82%, N = 28); most (75%,
N = 24) patients were actively receiving BCC
treatment. Both groups reported similar
symptoms, with the most common being red
lesions or open sores that failed to heal (41%,
N = 14) and cancer-related stress (41%, N = 14).
G2 reported more frequent and severe HRQL
impact as a result of their cancer condition
because most were affected in their daily
activities (76%, N = 16) or emotional
well-being (71%, N = 15). Cosmetic and
functional impacts were relevant and
important aspects of HRQL for both patient
groups (G1: 31%, N = 4; G2: 48%, N = 10).
Conclusions: Patients with non-advanced or
locally advanced and metastatic BCC
experience disease-related symptoms that
affect their HRQL, activities of daily living,
emotional well-being, and social and/or leisure
activities. Qualitative descriptions of patient
experiences can help healthcare providers and
caregivers better understand the impact of BCC
from the patient perspective.
Funding: Eli Lilly and Company.
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Dermatology; Health-related quality of life
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Non-advanced BCC; Non-melanoma skin
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common
cancer among fair-skinned individuals, with a
wide range in age-standardized annual incidence
by country from approximately 44–745 per
100,000 for women and 54–1041 per 100,000
for men in Germany and Australia, respectively
[1–3]. The incidence of non-melanoma skin
cancer (NMSC), and specifically BCC, is
increasing worldwide. The incidence of NMSC
procedures in the USA has almost doubled since
1994, and the total number of new cases in 2006
was estimated at 3.5 million per year,
approximately 80% of which were BCC [4]. By
2030, it is anticipated that the number of cases
presenting to dermatologists could increase by
an estimated 50% [5]. Given that primary BCCs
occur mostly on the areas of the body with the
greatest sun exposure, approximately 70% occur
on the head or face [6]. Less than 5% of all BCC
cases become locally advanced or metastatic [7].
However, if untreated, these lesions can cause
substantial local tissue destruction and
disfigurement [8]. Most BCC lesions can be
removed through surgical measures; however, a
small percentage of patients are unsuitable for
surgery (because of the location or size of the
lesion) or develop a more advanced stage of
disease. These patients constitute a poorly
defined (but small) percentage of overall BCC
[9] and might have a greater disease impact [10].
Although several efforts have been made to
determine the impact of NMSCs on the
health-related quality of life (HRQL) of
patients [11–14], few studies have examined
the specific impact of BCC. Patient-reported
outcome (PRO) measures, such as the Skindex,
Dermatology Life Quality Index (DLQI), and
Short-form Health Survey-12 (SF-12), have been
administered in studies of NMSC; however,
these measures were designed to evaluate more
general aspects of HRQL for non-cancer skin
conditions [13, 15, 16]. Rhee et al. [17]
developed and validated the Skin Cancer
Index (SCI) to address the need for a
disease-specific HRQL instrument in NMSC;
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however, their study population was not BCC
specific and only focused on patients who
experienced skin cancer in the cervicofacial
region. Burdon-Jones et al. [18] recognized and
attempted to address the lack of knowledge
related to non-metastatic skin cancer PRO
measures by eliciting general opinions in
writing from patients with malignant
melanoma and NMSC, and concluded that a
disease-specific measure for patients with both
metastatic and non-metastatic disease was
needed. Shingler et al. [10] conducted a health
utility study that found that severe forms of
BCC can represent a significant psychological
and cosmetic burden to patients, but these
results were quantitative and did not give
patients the opportunity to describe the
burden in their own words. A recent study by
Mathias et al. [19], undertaken to develop a
BCC-specific PRO measure, found more
substantial impacts related to daily activities
and psychosocial effects in patients with more
advanced stages of disease (locally advanced,
metastatic BCC) compared with patients with
basal cell nevus syndrome. However, consistent
with Shingler et al. [10], Mathias et al. [19] did
not provide an in-depth qualitative
understanding of the patients’ perspectives.
Given that little has been done to fully
understand experiences of BCC directly from
patients, the primary objective of this study was
to better characterize symptoms, the
bothersomeness of symptoms, and the HRQL
impact of BCC on the daily lives of patients
across different stages of the disease. A
secondary objective was to compare
descriptively the experiences, symptoms, and
HRQL impact of patients with non-advanced
(including only superficial or nodular histology)
BCC with those of patients with locally
advanced or metastatic disease.
METHODS
Study Design
This was a cross-sectional, qualitative study
involving 34 telephone interviews with
patients with BCC. Patients were recruited into
two study groups depending on their disease
stage using the American Joint Committee on
Cancer (7th edn) staging criteria [20]: group 1
(G1) included patients with stage 1,
non-advanced, BCC and group 2 (G2)
included patients with locally advanced or
metastatic BCC. Most patients (N = 32) were
recruited from three clinical sites in the USA
(two in California and one in Michigan). Two
patients with BCC were recruited as part of a
qualitative interview study (I4J-MC-HHBB [1.3])
that was being run in parallel to an
ongoing, phase I, dose-escalation study
(ClinicalTrials.gov #NCT01226485) for patients
with advanced cancer (including a locally
advanced or metastatic BCC group). All
patient recruitment took place over the course
of 10 months (March 2013–December 2013).
This parallel interview study was terminated
early because of a lack of enrollment, but the
data from the two interviews were included in
the current analysis.
Institutional review board (IRB) approval was
obtained before the start of the study and all
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013, and Good Clinical Practices. All patients
provided written informed consent before the
start of the interview.
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Patient Recruitment
Patients were identified from patient databases
or medical records at each clinical site or
through participation in the ongoing clinical
trial (ClinicalTrials.gov #NCT01226485). All
patients were required to be aged 18 years or
older, be able to participate in a telephone
interview in English, and have the presence of
measurable disease at the time of screening as
defined by the Response Evaluation Criteria in
Solid Tumors (RECIST 1.1). All patients had
active disease that was either newly diagnosed
or recurrent; G1 had been diagnosed with
non-advanced BCC (including only superficial
or nodular histology) and all patients in G2 had
a diagnosis of BCC that was locally advanced or
metastatic [20]. There were no restrictions based
on location of the patients’ lesion(s) for
participation in the study. Patients were not
eligible if they had a clinically relevant medical
or psychiatric condition that, in the opinion of
the investigator or site coordinator, would
interfere with the patient’s ability to complete
the study.
Data Collection
All patients were screened over the telephone
by site coordinators for inclusion in the study.
Informed consent forms were mailed to patients
and reviewed with scientific staff over the
telephone before the start of the interview.
Verbal and written informed consent was
obtained from each patient. Patients
participated in one telephone interview lasting
between 60 and 90 min. All scientific staff was
trained in the appropriate interview methods
and conducted all interviews using a
semistructured interview guide. A qualitative
methodology was used by applying a
combination of ‘open-ended’ questions and
probing techniques intended to elicit patients’
own description of their experiences with BCC
[21]. Interviews were conducted until saturation
(or the point at which no new concepts
emerged in the interview) was reached.
Interview notes were systematically reviewed
to enable continuous assessment of concepts
over the course of the study and notes were
tabulated to enable saturation to be assessed
separately for each group of patients. Patients
were asked to describe their cancer condition,
current BCC-specific symptoms as well as HRQL
impacts over the previous 7 days. Interviewers
probed on each symptom mentioned, asking
about intensity, severity, duration, bother, and
any related limitations; understanding the
impact of BCC-specific treatments was not
within the scope of this research. Patients also
provided demographic and BCC treatment
information for descriptive purposes. A clinical
form was completed for each patient by the site
investigator (excluding patients who
participated in the parallel interview study
[I4J-MC-HHBB {1.3}]) outlining the length of
time since BCC diagnosis, as well as prior and/or
current therapies that patients were receiving
for their BCC. All patients were reimbursed for
their participation according to the fair market
value based on the effort required for
participation in the study.
Data Analysis
Descriptive summary statistics were used to
summarize demographic and clinical
information. A content analysis approach [22]
was used to analyze the data (based on notes,
transcripts, and audio recordings) from the
telephone interviews. A coding dictionary
based on the semistructured interview guide
was developed before completion of data
collection to ensure that interview transcripts
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were coded objectively and consistently. A
qualitative analysis software program, ATLAS.ti
(Muhr T. ATLAS.ti 5.0 edn. Berlin, Germany:
ATLAS.ti Scientific Software Development
GmbH; 2004), was used to organize and
categorize systematically the text in the
interview transcripts. Using a content analysis
approach, the data were examined for general
themes, as well as specific issues and concerns
associated with BCC symptoms and impacts,
with a focus on words or phrases that patients
used to describe symptoms associated with the
condition. All patient data for the analysis were
deidentified before review by the sponsor of the
study and co-authors.
RESULTS
Clinical and Demographic Characteristics
Thirty-four patient interviews were conducted
(G1: N = 13; G2: N = 21). G1 comprised 11
patients with superficial subtype and two
patients with nodular subtype BCC. G2
comprised 12 patients with metastatic BCC
and nine patients with locally advanced BCC.
Importantly, as data were collected, similar
trends were observed in patient responses at
an earlier time point for patients with
non-advanced disease versus advanced disease;
as a result, a smaller number of patients were
recruited in G1.
The overall sample was mostly split
between patients aged 55–64 years (32%,
N = 11) and those aged 76? years (32%,
N = 11), and comprised primarily men (82%,
n = 28). In G1, most patients (77%, N = 10)
were older than 65 years, whereas, in G2,
approximately half (48%, N = 10) were aged
55–64 years (Table 1). Almost half of the
patients (47%, N = 16) were married or living
with a partner and most patients (53%,
N = 18) were retired or disabled. All patients
had some form of health insurance, with more
than half (59%, N = 20) using Medicare for
coverage. Approximately half (56%, N = 19)
reported having lived in a ‘high-sun’ area
when they were 10–20 years old, although a
greater proportion of patients in G1 (92%,
N = 12) communicated that they were
exposed to sun ‘a lot’ during that time
compared with patients in G2 (57%, N = 12).
A high-sun area was not defined by
geographical location, but rather was based
on patient self-report and investigator
discretion. Although more patients in G1
(69%, N = 9) reported having frequent
sunburns when younger, fewer in G1 (38%,
N = 5) reported having skin that burned easily
compared with those in G2 (47%, N = 9).
Treatment History
Across both groups, most patients (84%,
N = 27) had received pharmacologic therapy
or had undergone procedures for BCC before
the interview (Table 2). Surgical excision (53%,
N = 17) and Moh’s surgery (37%, N = 12) were
the most common treatments received (by at
least one-third of patients in each group).
Almost half of the patients in G2 (47%, N = 9)
had received vismodegib at some point
previously. In terms of current treatment,
most patients (75%, N = 24) were receiving
some form of treatment, with almost equal
amounts in both groups (G1: 77%, N = 10; G2:
74%, N = 14). Of those currently receiving
treatment, vismodegib was the most common
pharmacologic treatment at the time of their
interview (19%, N = 6), which was recorded
only for patients in G2, in line with the
regulatory approved indication.
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Age (years), N (%)
35–44 1 (3) 0 (0) 1 (5)
45–54 3 (9) 2 (15) 1 (5)
55–64 11 (32) 1 (8) 10 (48)
65–75 8 (23) 5 (38) 3 (14)
76? 11 (32) 5 (38) 6 (29)
Male gender, N (%) 28 (82) 10 (77) 18 (86)
Marital status, N (%)
Single, never married 5 (15) 0 (0) 5 (24)
Married and/or living with partner 16 (47) 6 (46) 10 (48)
Divorced 9 (26) 6 (46) 3 (14)
Widowed 4 (12) 1 (8) 3 (14)
Employment status, N (%)
Employed, part-time 2 (6) 0 (0) 2 (9)
Employed, full-time 9 (26) 4 (31) 5 (24)
Retired 16 (47) 7 (54) 9 (43)
Disabled 2 (6) 0 (0) 2 (9)
Unknown 5 (15) 2 (15) 3 (14)
Highest level of education completed, N (%)
Less than high school 2 (6) 1 (8) 1 (5)
GED/high-school equivalent 4 (12) 1 (8) 3 (14)
Some college 6 (18) 1 (8) 5 (24)
Graduated 2-year college 3 (9) 2 (15) 1 (5)
Completed college degree 7 (21) 5 (38) 2 (9)
Some postgraduate education 1 (3) 0 (0) 1 (5)
Completed postgraduate degree 9 (26) 3 (23) 6 (29)
Vocational training 2 (6) 0 (0) 2 (9)
Type of insurance, N (%)a
Medicare 20 (59) 9 (69) 11 (52)
Medicaid 2 (6) 1 (8) 4 (19)
Private health plan 14 (41) 5 (38) 9 (43)
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Diagnosis and Perceived Severity
of Disease
A greater proportion of patients in G2 (57%,
N = 12) considered their condition to be more
severe compared with patients in G1 (23%,
N = 3). When characterizing the severity of
their cancer, all patients mentioned the
impact on their lifestyle and life expectancy,
as well as the quantity and frequency of lesions
appearing. In addition, patients in G2 discussed
the emotional distress of the cancer when
describing their disease severity, whereas
patients in G1 did not. Three patients (G1:
8%, N = 1; G2: 9%, N = 2) had difficulty
deciding on the severity of their cancer
because of the discord between the severity
reported by their doctor compared with their
own understanding of their health and skin
cancer condition. The way in which patients
were first found to have BCC was almost
identical in both groups, with the exception of
three patients in G2, who reported waiting
longer to seek treatment, thus resulting in
more severe disease and greater impact, such
as disfigurement. Most patients (G1: 61%,
N = 8; G2: 67%, N = 14) sought medical care
because of physical symptoms, such as lesions
or bumps, which resulted in a diagnosis. Other
patients (G1: 31%, N = 4; G2: 33%, N = 7)
reported going to the doctor for unrelated
reasons, such as a routine physical
examination, when they were first found to
have BCC.
Patients in both groups mentioned
experiencing growths in similar locations on
their bodies, such as their face, arms, chest,
scalp, or head. Patients in G2 also reported
lesions on their back and neck. Most patients
(76%, N = 16) in G2 described their lesions as
‘visibly apparent’ to others, compared with 23%
(N = 3) in G1. Patients in G2 also tended to
experience more lesions at a given time and had











Other insurance 9 (26) 6 (46)b 3 (14)c
Location of residence during ages 10–20 years
considered a high-sun area, N (%)
19 (56) 6 (46) 13 (62)
Exposed to sun a lot between age of 10–20 yearsd, N (%) 24 (71) 12 (92) 12 (57)
Frequent sunburns when youngerd, N (%) 17 (50) 9 (69) 8 (38)
Skin burns easilyd,e, N (%) 14 (44) 5 (38) 9 (47)
ERP extended reporting period, GED general education development, MCE medicaid coverage expansion, VA veterans
health association
a Not mutually exclusive
b Other (N) includes VA System (N = 5) and ERP Supplement (N = 1)
c Other (N) includes VA System (N = 1), VA Health Insurance (N = 1), and MCE. On the county system (N = 1)
d Based on self-reported experience with sun exposure; responses included ‘yes’ responses only
e Does not include patients recruited from the NCT01226485 study (N = 2); denominator of N = 32 was used for this
question
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Years receiving care at practicea
Mean (SD) 4.9 (6.8) 4.4 (5.3) 5.3 (7.8)
Range 0.1–30.0 0.1–20.0 0.1–30.0
Years since BCC diagnosis
Mean (SD) 8.0 (12.0) 2.9 (6.8) 11.4 (13.6)
Range 0.0–43.0 0.0–24.0 0.0–43.0
Previous treatment procedures, medication, or chemotherapy for BCC, N (%)b
Yes 27 (84) 10 (77) 17 (89)
Electrodessication and curettage 2 (6) 2 (15) 0 (0)
Surgical excision 17 (53) 8 (61) 9 (47)
Chemotherapy 1 (3) 0 (0) 1 (5)
Radiation 3 (9) 0 (0) 3 (16)
Vismodegib 9 (28) 0 (0) 9 (47)
Pain medications 1 (3) 0 (0) 1 (5)
Topical (5-FU, imiquimod) 1 (3) 1 (8) 0 (0)
Moh’s surgery 12 (37) 5 (38) 7 (37)
Otherc 2 (6) 0 (0) 2 (10)
None 5 (16) 3 (23) 2 (10)
Current treatment procedures, medication, or chemotherapy for BCC, N (%)b
Yes 24 (75) 10 (77) 14 (74)
Electrodessication and curettage 1 (3) 1 (8) 0 (0)
Surgical excision 5 (16) 3 (23) 2 (10)
Radiation 1 (3) 0 (0) 1 (5)
Vismodegib 6 (19) 0 (0) 6 (32)
Pain medications 3 (9) 1 (8) 2 (10)
Topical (5-FU, imiquimod) 2 (6) 2 (15) 0 (0)
Moh’s surgery 4 (12) 2 (15) 2 (10)
Otherd,e 7 (22) 3 (23)d 4 (21)e
None 8 (25) 3 (23) 5 (26)
Table does not include two patients from NCT01226485 clinical trial
5-FU ﬂuorouracil, PDT photodynamic therapy, SD standard deviation
a Deﬁned as the number of years a patients has been receiving care at the recruiting medical site
b Responses are not mutually exclusive
c Other (N = 2) includes clinical trial (N = 1) and ﬁne-needle aspiration (N = 1)
d Other (N = 3) includes pending Moh’s surgery in January 2014 (N = 1), shave biopsy (N = 1), and sunscreen (N = 1)
e Other (N = 4) includes arsenic trioxide (N = 2), following with oncologist (N = 1), and oculoplastics, ear, nose, throat
(ENT) bone excision, and probably postoperative radiation (N = 1)
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Symptoms
The symptoms reported by patients were
common across groups, and almost all patients
in G1 (85%, N = 11) and G2 (95%, N = 20) were
experiencing at least one symptom related to
their BCC at the time of the current study
(Table 3). Patients in G2 reported a larger
number of different symptoms and a greater
frequency of specific symptoms compared with
patients in G1. The most frequently reported
symptoms overall were red lesions or open sores
that failed to heal (41%, N = 14) and
cancer-related stress (41%, N = 14). Among












Red lesions or open sores 14 (41) 7 (54) 7 (33)
Cancer-related stress 14 (41) 5 (38) 9 (43)
Itching localized to the lesion 13 (38) 6 (46) 7 (33)
Pain related to cancer 10 (29) 0 (0) 10 (48)
Bleeding lesions 9 (26) 4 (31) 5 (24)
Problems sleeping 8 (23) 2 (15) 6 (29)
Lack of energy 3 (9) 0 (0) 3 (14)
Hair loss 3 (9) 1 (8) 2 (9)
Depression 2 (6) 0 (0) 2 (9)
Muscle cramps 2 (6) 0 (0) 2 (9)
Dizziness 1 (3) 0 (0) 1 (5)
Skin discoloration 1 (3) 1 (8) 0 (0)
Impacts
Daily activities 22 (65) 6 (46) 16 (76)
Emotional well-being 21 (62) 6 (46) 15 (71)
Social and/or leisure activities 15 (44) 4 (31) 11 (52)
Cosmetic and functional 14 (41) 4 (31) 10 (48)
Work and/or studies 9 (26) 2 (15) 7 (33)
Personal relations 9 (26) 2 (15) 7 (33)
Sexual activities 5 (16) 1 (8) 4 (19)
a Includes only patients who reported symptoms related speciﬁcally to their cancer; all treatment-related symptoms were
excluded from the analysis and reporting
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patients in G2, red lesions or open sores that
failed to heal were more commonly reported by
patients with locally advanced disease (38%,
N = 5/13), whereas cancer-related stress was
largely reported by patients with metastatic
disease (75%, N = 6/8). Other commonly
reported symptoms included itching localized
to the lesion site (38%, n = 13), bleeding lesions
(26%, N = 9), and problems sleeping (23%,
N = 8). Pain related to cancer was frequently
reported by G2 patients only (48%, N = 10).
At the conclusion of the interview, patients
were asked which symptoms they considered
the ‘most bothersome’. Most patients in G2
(95%, N = 20) identified one or more symptoms
as most bothersome compared with 69%
(N = 9) of patients in G1. Patients in G1
(N = 4) had greater difficulty in identifying a
bothersome symptom because they either had
only one symptom or did not consider their
symptoms to be bothersome. Across both
groups, of the 29 patients who reported at
least one bothersome symptom, the most
commonly reported were cancer-related stress
(24%, N = 7), itching localized to the lesion
(24%, N = 7), and open sores that failed to heal
(14%, N = 4) (Table 4).
Impact
All patients were asked whether their BCC had
impacted their daily activities, emotional
well-being, social or leisure activities, work or
studies, personal relations, or sexual activities
over the previous 7 days. Table 3 summarizes
this impact quantitatively.
Daily Activities
A greater proportion of patients (76%, N = 16)
in G2 reported experiencing some impact on
daily activities compared with those in G1
(46%, N = 6). When asked how their cancer
had affected their daily activities, 31% (N = 4)
of patients in G1 and 57% (N = 12) of patients
in G2 mentioned having to limit activities, such
as exercise, strenuous activities, such as lifting
heavy objects, or outdoor activities, to avoid
sun exposure.
Patients in G2 (19%, N = 4) also mentioned
experiencing fatigue, which limited their ability
to complete chores or other household activities,
whereas patients in G1 (31%, N = 4) mentioned
needing to be more cautious when doing
activities as a result of surgeries or symptoms.
One patient in G1 and four patients in G2
mentioned having to change their schedules and
daily activities because of doctor’s appointments
or when recovering from surgeries.
Emotional Well-Being
Compared with G1, a greater proportion of
patients in G2 reported being emotionally
impacted by the disease (G1: 46%, N = 6; G2:
71%, N = 15). Approximately half of the
patients in G2 (48%, N = 10) reported feeling
self-conscious or embarrassed about their
appearance because of the scarring or
appearance of the lesions. Nineteen percent
(N = 4) and 23% (N = 3) of patients in G2 and
G1, respectively, mentioned being bothered by
others staring at their lesions or scars.
Patients also reported being worried,
stressed, or concerned about their health and
the cancer (G1: 8% N = 1; G2: 24% N = 5) and
being frustrated or upset with the reoccurrence
of the cancer (G1: 15% N = 2; G2: 19%, N = 4).
A few patients in G1 (15%, N = 2) and G2 (14%,
N = 3) mentioned being depressed because of
their cancer.
Social Impact
About half of the G2 patients (52%, N = 11) and
one-third of G1 patients (31%, N = 4) reported
an impact on their social or leisure activities
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4 (14) ‘‘Yeah, it wouldn’t heal over, like a—if you—if
I’d jabbed it with a knife or something it
would heal, but, uh, this was just a little sore
that, uh, whenever I washed my face if it had
any kind of a scab on there, it would come off
and wouldn’t heal.’’ (Pt ID: 002-201)
‘‘Yeah, an open bleeding wound, well, it would
bleed sometimes and sometimes not. And,
uh, it starts off a little slow, but just keeps
growing bigger and bigger and eating more
and more, uh, outward ﬂesh.’’ (Pt ID:
002-103)
‘‘So it starts small and gets bigger and you said
an open bleeding wound?’’ (Interviewer)
‘‘Uh-huh [yes], the doctors call it moth eating,
when the wound ﬁnally opens up, so that’s
how they describe it.’’ (Pt ID: 002-103)
Cancer-related
stress
7 (24) ‘‘Immediately around the time of being
biopsied and ﬁnding the results, I’d say that
for me is pretty severe. Now I’m just sort of
waiting to get through the process, and then
it’s going to be very stressful the day of the
surgery and the day after for sure. And then,
it just sort of levels off again.’’ (Pt ID:
003-201)
‘‘I’d say stress related to the cancer is the most
bothersome and biggest issue…there’s an
unknown component whether it’s going to
heal or not and whether it’s going to leave
physical scars or not.’’ (Pt ID: 001-208)
‘‘Um, when I get upset because of the stress, uh,
it—it becomes—you know, yes, I’m bothered
by it. On, uh, a daily thing when I’m not
doing anything great or anything and I don’t
get worked up, uh, I think the, uh,
medication works ﬁne and I can control it.
But it’s just when things start going
backwards, which they do quite a lot, um,
then it starts becoming an issue.’’ (Pt ID:
002-103)
‘‘Probably—at this point, probably the stress of
the unknown because I know the itching will





7 (24) ‘‘Um, I have itching or, um, a discomfort, it’s
like, uh, a sore or a mosquito bite or
something that’s there, you know.’’ (Pt ID:
001-204)
‘‘It—uh, it’s bothersome, you know, it’s like
any itch you have, you want to scratch it. You
know you shouldn’t in this case and that—
that’s what’s, uh, the bother really.’’ (Pt ID:
002-201)
‘‘Itching and—uh, itching and burning because
that causes—when I rub that it causes it to
bleed. You know, even if you rub on the side
of it or something, uh, then the scab comes
off. So the itching is what triggers it.’’ (Pt ID:
003-105)
The symptoms listed were described by patients as their most bothersome symptoms during the interview discussion
Pt ID patient identiﬁer
a A denominator of 29 was used to calculate the percentages; this is based on the total number of patients who reported at
least one ‘most bothersome’ symptom
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because of their cancer. The most common
reasons included having to reduce outdoor
activities (G1: 15%, N = 2; G2: 24%, N = 5),
such as hiking, gardening, and going to watch
baseball games, as well as spending less time
with friends and family (G1: 23%, N = 3; G2:
24%, N = 5) because of their appearance.
Patients also reported that the time spent
Table 5 Patient quotes regarding impacts and change in behavior
Impact on
HRQL
Group 1: non-advanced Group 2: locally advanced and/or metastatic
Daily activities ‘‘Well, like, right now because this is still a bit of an open
wound, you know, I have to be careful I, you know,
don’t pump my heart rate up too high at the gym and
things like that.’’ (Pt ID: 003-201)
‘‘Well, I’m stuck inside, like I said. I—I mean, I
can jump in the car and go to the store and
stuff. But I’m limited to doing normal things
of going outside, maybe going to a—to a
baseball game, or going to the park and just
going…for a walk. I can’t do any of those
things.’’ (Pt ID: 001-018)
Emotional
well-being
‘‘Uh, I’m tired of having my body cut. I mean, you could
say it’s at times mildly depressing.’’ (Pt ID: 001-205)
‘‘You know, I know it’s, now that I know what
it is, I want to get rid of it. But, I know other
people see it on my skin and wonder what
that is. I don’t know.’’ (Pt ID: 001-103)
‘‘Well, I don’t—I don’t like it when people
stare at me. Um, it makes me a little bit
uneasy; especially the little children. That
bothers me.’’ (Pt ID: 001-016)
Social impact ‘‘Yeah, I’m not as motivated, you know, I just—I’m tired,
uh, when you’re not sleeping you don’t have that
energy to go—to go out there and—and do those
things [hiking with dog or going snowshoeing with
friends]. I—I try to push myself too when I have a
good days, but there’s been a lot more bad days.’’
(Pt ID: 002-202)
‘‘I don’t know if it’s leisure, but it’s basically all
the yard work. Back when they were open
sores it would stop [me from] meeting
people—talking to people and basically




‘‘Well, I wear the hat and the wig because after all these
surgeries I—I have no hair, it’s all scar tissue and [sigh]
I think my mind has shut down.’’ (Pt ID: 002-202)
‘‘Uh, a great, gaping wound on my face and no
ears, I mean as soon as you look at me you
can tell something is deﬁnitely wrong with
this guy.’’ (Pt ID: 002-103)
Change in
behavior
‘‘Um, the only change in lifestyle that I’ve done, as a
result of the cancers, is I am much more aware of being
in the sun without some sort of protection.’’ (Pt ID:
001-205)
‘‘I might go outside and that sun hits this open
wound on the side of my face it’s just like
putting it in a fry pan. I always wear a great
big broad brim hat and stuff, um, when I go
outside.’’ (Pt ID: 002-103)
HRQL health-related quality of life, Pt ID patient identiﬁer
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receiving medical treatment (including
transportation) limited their activities.
Cosmetic and Functional Impact
Cosmetic and functional impacts resulting from
cancerous lesions or cancer-related surgeries
were described by patients in both groups.
Almost half of G2 patients (48%, N = 10)
described functional and cosmetic impacts,
such as visible scarring (9%, N = 2),
malformation of the skin because of the
cancerous lesions (24%, N = 5), or having part
or all of a body part (i.e., ears or eyes) removed
because of surgery (19%, N = 4). One-third of
patients in G1 (31%, N = 4) were concerned
with the need for repeat surgeries and the
potential for scarring, especially in places on
the body that were highly visible to others.
Patients across both groups also communicated
a feeling of fear, stress, and embarrassment
associated with the cosmetic and functional
impacts.
Changes in Behavior
Changes in behavior were reported almost
equally across both groups (G1: 100%, N = 13;
G2: 91%, N = 10/11); limitations on sun
exposure were reported most commonly (G1:
92%, N = 12; G2: 82%, N = 9/11). Almost half
of the patients in both groups (G1: 38%, N = 5;
G2: 48%, N = 10) reported wearing additional
clothing to protect themselves from the sun and
wearing a hat when going outside (G1: 31%,
N = 4; G2: 24%, N = 5). Patients also reported
reducing or limiting sun exposure by wearing
sunscreen or seeking shaded areas.
A few patients in both groups (G1: 15%,
N = 2; G2: 36%, N = 4/11) mentioned having to
alter their clothing as a result of their surgeries
by wearing more loosely fitted clothing or
wearing clothing to hide a symptom of the
cancer, such as a red lesions or open sores.
Select patient quotations characterizing
BCC-specific impacts and changes in behavior
affecting HRQL are documented in Table 5.
DISCUSSION
Although several efforts have been made to
determine the impact of NMSC on HRQL, few
studies have examined the specific impact of
BCC. This study was conducted to generate
descriptive information specific to BCC.
Importantly, patients with either non-advanced
or locally advanced or metastatic BCC
experienced symptoms and impacts from their
disease that affected their HRQL. Although there
were some commonalities between the two
groups, there were some key differences that
are important to highlight.
Overall, a greater proportion of patients with
locally advanced or metastatic disease deemed
their condition to be severe compared with
patients with non-advanced disease. Patients in
G2 were more likely to describe frequent and
bothersome symptoms and expressed
experiencing a greater HRQL impact across six
of the seven categories evaluated compared with
patients in G1. Pain related to cancer was reported
by approximately half of G2 patients, whereas it
was not reported by any patient in G1. Similar to
Mathias et al. [19], the current study found that
impacts on emotional well-being and daily
activities were common and more frequently
reported in patients with more advanced
disease. Consistent with Shingler et al. [10], the
current study also found that BCC imposes a
significant psychological and cosmetic burden on
patients, as demonstrated by approximately 50%
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of G2 experiencing visible scarring, malformation
of the skin, or loss of a body part.
Although more subtle, disease stages that are
non-advanced can impose bothersome sequelae
and negative impacts on patients’ HRQL.
Despite the relatively small sample size of G1,
approximately half of patients reported the
disease as having a negative impact on their
emotional well-being and daily activities. In
addition, anxiety related to potential or existing
scarring, as well as tumor recurrence, was
communicated by one-third of the sample.
These findings, similar to those of
Burdon-Jones et al. [18], suggest that, although
the burden can be less when compared with
those with more advanced disease, it is
important to assess HRQL in all patients with
BCC. In our study, the domains or themes that
emerged as the most important to assess a
patient’s HRQL across both groups included
cosmetic and functional impacts, emotional
well-being, and changes in behavior and daily
activities to avoid sun exposure. These domains,
particularly the fear of scaring and disfigurement
and the importance of avoiding excess sun, also
corresponded to the important themes identified
by Burdon-Jones et al. [18], providing additional
evidence to support the impact of these domains
in the BCC patient population.
In addition, the findings from this study also
suggest that, although is it important to
evaluate the HRQL in both groups of patients,
different aspects of the HRQL domains are more
relevant based on the stage of the disease. For
example, the impact on daily activities is an
important domain to measure in both
populations. Most patients with non-advanced
disease experienced cutaneous surface-level
symptoms, such as red spots or localized
itching, which tended to affect daily activities
that pertained to limiting sun exposure or
modifying clothing selections. However, in
patients with more advanced disease, the daily
activities affected were changes in lifestyle, such
as the inability to clean the house or reductions
in exercise. Based on these differences, PROs in
the local disease population should focus on
these initial behavioral changes in terms of
daily impact, whereas patients with advanced
disease should be more broadly assessed, given
the number of activities limited by their
condition.
In addition, because of the number of
patient comments regarding healthcare
utilization and time burden, it would be useful
to examine the healthcare resource utilization
in both patient groups to gain a better
understanding of the economic and time
burden associated with BCC. Many patients
were currently undergoing treatment at the
time of the interviews, and both patient
groups mentioned the burden associated with
treatment, such as scheduling appointments,
the cost of the procedures, and reduced or loss
of productivity while recovering from surgery.
Although the study was intended to
characterize the patient population, several
limitations should be considered when
interpreting these results. Patients for both
groups were difficult to recruit. Given the
accessibility and effectiveness of surgery in
those with non-advanced disease, many
eligible patients did not have current baseline
disease and were ineligible for the study. This
requirement of measurable disease, however,
reduced the possibility of recall bias which
could otherwise have been considered as an
additional limitation to these results. Likewise,
the recruitment of patients with locally
advanced and metastatic disease was difficult
because of the rarity of this advanced disease
stage. This resulted in a long recruitment period
for a limited number of interviews and a sample
of patients from only two states (California and
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Michigan), which decreases the generalizability
of these results. In addition, because of the
difficulty in recruiting patients, all qualitative
interviews were conducted over the telephone
and not in person. Although not ideal for
facilitating communication between patients
and interviewers, conducting qualitative
interviews by telephone did enable increased
patient participation, especially for those
patients who had progressive disease or were
older and being cared for by another. Other
limitations that should be taken into
consideration include the relatively few female
participants, as well as other variables not
controlled for in this study that could inform
patients’ impressions of their disease (i.e.,
education regarding BCC, experience of family
or friends with BCC, or impact of treatments).
A strength of the study was the use of
qualitative methodology, which enabled
exploration of concepts with patients in a not
well-understood population. In addition,
conducting interviews with patients at varying
stages of disease provided an understanding of
HRQL along the progression of disease, which
has not been previously done.
This study provides insight into a patient
population that has not previously been well
defined in the literature. Future studies with a
broader scope might be interested in
highlighting similarities and/or differences
between BCC and other types of skin
malignancy in terms of disease symptoms and
HRQL impact. Although the information
gained from this study fills a gap in the
scientific literature and supports the
development of measurements to evaluate
new therapies, studies in larger numbers of
patients with BCC (including a greater
proportion of women) are warranted to refine
the concepts most relevant to this population
of patients.
CONCLUSION
Patients with non-advanced or locally advanced
and metastatic BCC experience disease-related
symptoms that affect their HRQL, activities of
daily living, emotional well-being, and social
and/or leisure activities. Providing this patient
perspective on important symptoms and HRQL
impact helps to more broadly characterize the
influence of different disease stages of BCC on
the daily life of patients and provides a
foundation for additional refinement of
concepts most relevant to them.
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